P

Porton Pharma Solutions Ltd
SZSE:300363

Watchlist Manager
Porton Pharma Solutions Ltd
SZSE:300363
Watchlist
Price: 17.2 CNY -5.29% Market Closed
Market Cap: 9.4B CNY
Have any thoughts about
Porton Pharma Solutions Ltd?
Write Note

Porton Pharma Solutions Ltd
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Porton Pharma Solutions Ltd
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
P
Porton Pharma Solutions Ltd
SZSE:300363
Long-Term Debt
ÂĄ1.7B
CAGR 3-Years
127%
CAGR 5-Years
60%
CAGR 10-Years
40%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Long-Term Debt
ÂĄ104.5m
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Long-Term Debt
ÂĄ158.1m
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
-6%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Long-Term Debt
ÂĄ58.3m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Long-Term Debt
ÂĄ195.6m
CAGR 3-Years
43%
CAGR 5-Years
118%
CAGR 10-Years
42%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Long-Term Debt
ÂĄ192.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Porton Pharma Solutions Ltd
Glance View

Market Cap
9.4B CNY
Industry
Pharmaceuticals

Porton Pharma Solutions Ltd. engages in the research and development and manufacture of pharmaceutical products and active pharmaceutical ingredients. The company is headquartered in Chongqing, Chongqing and currently employs 3,782 full-time employees. The company went IPO on 2014-01-29. The firm is also engaged in the multi-client product manufacturing businesses and pharmaceutical and chemical commerce businesses. The products of the Company include anti-viral, anti-diabetic, hypolipidemic, anti-cancer, anesthesia analgesia and anti-bacterial pharmaceuticals, among others. The firm operates its businesses in Europe, North America, Asia and China, among others.

Intrinsic Value
20.26 CNY
Undervaluation 15%
Intrinsic Value
Price
P

See Also

What is Porton Pharma Solutions Ltd's Long-Term Debt?
Long-Term Debt
1.7B CNY

Based on the financial report for Sep 30, 2024, Porton Pharma Solutions Ltd's Long-Term Debt amounts to 1.7B CNY.

What is Porton Pharma Solutions Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
40%

Over the last year, the Long-Term Debt growth was 49%. The average annual Long-Term Debt growth rates for Porton Pharma Solutions Ltd have been 127% over the past three years , 60% over the past five years , and 40% over the past ten years .

Back to Top